Loading clinical trials...
Loading clinical trials...
A Randomized Double Blind Placebo And Active Controlled Parallel Group Phase 2 Study To Evaluate PF-05089771 As A Monotherapy And As An Add-on To Pregabalin For The Treatment Of Painful Diabetic Peripheral Neuropathy
Conditions
Interventions
PF-05089771 150 mg
Matched placebo for PF-05089771 150 mg and pregabalin 300 mg
+2 more
Locations
32
United States
Clinical Research Consortium Arizona
Phoenix, Arizona, United States
Arizona Research Center
Phoenix, Arizona, United States
Neuro-Pain Medical Center
Fresno, California, United States
Meridien Research
Bradenton, Florida, United States
PAB Clinical Research
Brandon, Florida, United States
Pulmonary Associates of Brandon (PAB)
Brandon, Florida, United States
Start Date
November 10, 2014
Primary Completion Date
July 15, 2015
Completion Date
September 28, 2015
Last Updated
May 5, 2017
NCT06152887
NCT00159679
NCT03047278
NCT00507936
NCT00785577
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions